Everything below concerns freeze-thaw cycle. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
In 1928, Grace and Pan American Airways jointly formed Pan American-Grace Airways known as Panagra, establishing the first air link between North and South America, which began operation in 1929. In 1967, Panagra merged with Braniff International Airways.
The Northern Ireland Executive is restored after the DUP ends its two-year boycott; Sinn Féin's Michelle O'Neill is appointed First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. A third round of joint UK–US air strikes are launched against Houthi rebels, targeting three sites in Yemen. Defence Secretary Grant Shapps says the latest strikes are "not an escalation" of the conflict. Esther Martin, a 68-year-old woman, is killed by dogs while visiting her grandson for the weekend in Jaywick, near Clacton-on-Sea, Essex. 4 February – CCTV footage of alkali attack suspect Abdul Shakoor Ezedi in a Tesco store is shown by the police, as a reward of £20,000 is offered for information leading to his capture. 5 February Buckingham Palace announces that King Charles III has been diagnosed with cancer and will postpone public duties while undergoing treatment. The Met Office issues a yellow weather warning for snow for large parts of north Wales, and northern and central England, for 8 February as unseasonably mild temperatures are replaced by colder weather. A 16-year-old boy is found guilty of plotting to launch a terrorist attack at the Isle of Wight Festival following a trial at Kingston Crown Court. The UK government launches a six-week consultation on plans for Martyn's Law, which would make provisions to better protect the public against potential acts of terrorism.
== Origins of pathology == Early understanding of the origins of diseases constitutes the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. The Greek physician Hippocrates, the founder of scientific medicine, was the first to deal with the anatomy and the pathology of human spine. Galen developed an interest in anatomy from his studies of Herophilus and Erasistratus. The concept of studying disease through the methodical dissection and examination of diseased bodies, organs, and tissues may seem obvious today, but there are few if any recorded examples of true autopsies performed prior to the second millennium. Though the pathology of contagion was understood by Muslim physicians since the time of Avicenna (980–1037) who described it in The Canon of Medicine (c. 1020), the first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161) who proved that the skin disease scabies was caused by a parasite, followed by Ibn al-Nafis (b. 1213) who used dissection to discover pulmonary circulation in 1242. In the 15th century, anatomic dissection was repeatedly used by the Italian physician Antonio Benivieni (1443–1502) to determine cause of death. Antonio Benivieni is also credited with having introduced necropsy to the medical field. Perhaps the most famous early gross pathologist was Giovanni Morgagni (1682–1771).
=== Financing === In May 2016, Cerebras raised $27 million in a series A round led by Benchmark, Foundation Capital and Eclipse Ventures. In December 2016, the company raised a series B round led by Coatue Management. In January 2017, it raised a series C round led by VY Capital. In November 2018, Cerebras raised $88 million in a series D round, making the company a unicorn. Investors in this round included Altimeter, VY Capital, Coatue, Foundation Capital, Benchmark, and Eclipse. In November 2019, Cerebras raised $270 million in a series E round at a valuation of $2.4 billion. In November 2021, Cerebras raised $250 million in a Series F round, valuing the company at over $4 billion and bringing its total financing to $720 million. The Series F financing round was led by Alpha Wave Ventures and Abu Dhabi Growth Fund (ADG). In July, August, and September 2024, the company raised $85 million in a series F-1 round, selling shares for $14.66 each. In September 2025, the company raised $1.1 billion in a Series G round, selling shares for $36.23 each, or a valuation of $8.1 billion. In January 2026, the company raised $1.0 billion in a Series H round, selling shares for $89.01 each. In this round, Benchmark invested $225 million, while Alpha Wave and funds managed by Fidelity Investments each invested $100 million. On May 14, 2026, the company became a public company via the largest U.S. technology initial public offering since 2019, raising $5.55 billion by selling 30 million shares at $185 each and opening on Nasdaq at $350, valuing the company at $95 billion.
glycoprotein A protein with one or more carbohydrate molecules, typically short oligosaccharide chains, covalently attached to one or more of its amino acid side chains. Proteins exposed on the outer surface of the plasma membrane or secreted into the extracellular space are commonly modified in this way, after which they are said to be glycosylated.
Sources: en.wikipedia.org
=== Current AI methods and databases of predicted protein structures === AlphaFold2, was introduced in CASP14, and is capable of predicting protein structures to near experimental accuracy. AlphaFold was swiftly followed by RoseTTAFold and later by OmegaFold and the ESM Metagenomic Atlas. In a study, Sommer et al. 2022 demonstrated the application of protein structure prediction in genome annotation, specifically in identifying functional protein isoforms using computationally predicted structures, available at https://www.isoform.io. This study highlights the promise of protein structure prediction as a genome annotation tool and presents a practical, structure-guided approach that can be used to enhance the annotation of any genome. In 2024, David Baker and Demis Hassabis (along with John M. Jumper) were awarded the Nobel Prize in Chemistry for their contributions to computational protein modeling, including the development of AlphaFold2, an AI-based model for protein structure prediction. AlphaFold2's accuracy has been evaluated against experimentally determined protein structures using metrics such as root-mean-square deviation (RMSD). The median RMSD between different experimental structures of the same protein is approximately 0.6 Å, while the median RMSD between AlphaFold2 predictions and experimental structures is around 1 Å. For regions where AlphaFold2 assigns high confidence, the median RMSD is about 0.6 Å, comparable to the variability observed between different experimental structures.
This caused the "most monumental nonnuclear explosion and fire ever seen from space." However, the Soviet Union did not blame the United States for the attack. In 2009, president Barack Obama declared America's digital infrastructure to be a "strategic national asset," and in May 2010 the Pentagon set up its new U.S. Cyber Command (USCYBERCOM), headed by General Keith B. Alexander, director of the National Security Agency (NSA), to defend American military networks and attack other countries' systems. The EU has set up ENISA (European Union Agency for Network and Information Security) which is headed by Prof. Udo Helmbrecht and there are now further plans to significantly expand ENISA's capabilities. The United Kingdom has also set up a cyber-security and "operations centre" based in Government Communications Headquarters (GCHQ), the British equivalent of the NSA. In the U.S. however, Cyber Command is only set up to protect the military, whereas the government and corporate infrastructures are primarily the responsibility respectively of the Department of Homeland Security and private companies. On 19 June 2010, United States Senator Joe Lieberman (I-CT) introduced a bill called "Protecting Cyberspace as a National Asset Act of 2010", which he co-wrote with Senator Susan Collins (R-ME) and Senator Thomas Carper (D-DE). If signed into law, this controversial bill, which the American media dubbed the "Kill switch bill", would grant the president emergency powers over parts of the Internet.
In contrast to other mechanical disruption methods the Microfluidizer breaks the cell membranes efficiently but gently, resulting in relatively large cell wall fragments (450 nm), and thus making it easier to separate the cell contents. This can lead to shorter filtration times and better centrifugation separation. Microfluidizer technology scales from one milliliter to thousands of liters.
=== Evidence in mammals === Publishing in Science in 1961, Julius Axelrod found an N-methyltransferase enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung. This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals. From then on, two major complementary lines of evidence have been investigated: Localization and further characterization of the N-methyltransferase enzyme, and analytical studies looking for endogenously-produced DMT in body fluids and tissues. In 2013, researchers reported DMT in the pineal gland microdialysate of rodents. A study published in 2014 reported the biosynthesis of N,N-dimethyltryptamine (DMT) in the human melanoma cell line SK-Mel-147 including details on its metabolism by peroxidases. It is assumed that more than half of the amount of DMT produced by the acidophilic cells of the pineal gland is secreted before and during death, the amount being 2.5–3.4 mg/kg. Contrarily, this claim by Strassman has been criticized by David Nichols who notes that DMT does not appear to be produced in any meaningful amount by the pineal gland. Removal or calcification of the pineal gland does not induce any of the symptoms caused by removal of DMT. The symptoms presented are consistent solely with reduction in melatonin, which is the pineal gland's known function. Nichols instead suggests that dynorphin and other endorphins are responsible for the reported euphoria experienced by patients during a near-death experience.
== Inhibitors == Granzyme B's most common inhibitor is SERPINB9 also known as proteinase inhibitor nine (PI-9) which is 376 amino acids long and found in the nucleus and cytoplasm. It is produced by many types of cell to protect themselves from accidental granzyme B mediated cell death. PI-9 is metastable and forms an energetically favourable conformation when bound to granzyme B. The reactive loop centre (RCL) of the PI-9 molecule acts as a pseudosubstrate and initially forms a reversible Michaelis complex. Once the peptide bond of the RCL is cleaved between positions P1 and P1', granzyme B is permanently inhibited. However, if the RCL is cleaved efficiently, PI-9 does not act as a 1:1 suicide substrate and granzyme B is left uninhibited. Granzyme M can also cleave PI-9 in the nucleus and cytoplasm to relieve granzyme B of inhibition. Protein L4-100K from adenoviruses can also inhibit granzyme B by binding at exosites and specific binding pockets. L4-100K is an assembly protein that can transport hexon capsomeres into the nucleus of an adenovirus. 100k can be cleaved to a 90kDa fragment by granzyme H to relieve this inhibition which is important in adenovirus 5 infected cells.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.